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Abstract  
Transcription factors regulate their target genes by binding to regulatory regions in the 
genome. Although the binding preferences of TP53 are known, it remains unclear 
what distinguishes functional enhancers from non-functional binding. In addition, the 
genome is scattered with recognition sequences that remain unoccupied. Using two 
complementary techniques of multiplex enhancer-reporter assays, we discovered that 
functional enhancers could be discriminated from non-functional binding events by 
the occurrence of a single TP53 canonical motif. By combining machine learning with 
a meta-analysis of TP53 ChIP-seq data sets we identified a core set of more than one 
thousand responsive enhancers in the human genome. This TP53 cistrome is 
invariably used between cell types and experimental conditions, while differences 
between experiments can be attributed to indirect non-functional binding events. Our 
data suggest that TP53 enhancers represent a class of unsophisticated cell-autonomous 
enhancers containing a single TP53 binding site, distinct from complex 
developmental enhancers that integrate signals from multiple transcription factors. 
 
  
 Cold Spring Harbor Laboratory Press on June 20, 2016 - Published by genome.cshlp.orgDownloaded from 
  
 
  
 
3 
Introduction 
Enhancers are essential regulatory elements that are bound by transcription factors 
(TFs) to shape the gene expression network underlying a cellular phenotype. 
Understanding the enhancer code is crucial to achieve a functional regulatory 
annotation of the human genome, which is ultimately required to understand 
developmental processes and disease-related variation in the non-coding part of the 
genome. However, the complexity of the enhancer logic, their sparse distribution, 
context-specificity and distal location from genes in the genome make it challenging 
to identify and validate enhancers. During recent years, high-throughput sequencing 
efforts like ENCODE and the Epigenomics Roadmap have yielded an enormous 
wealth of regulatory data (Gerstein et al. 2012; Roadmap Epigenomics Consortium et 
al. 2015). Some of the most commonly used approaches are chromatin 
immunoprecipitation (ChIP-seq) to localize regions bound by a certain TF or a 
modified histone, and various assays aimed at localizing accessible and free regions 
within the genome (e.g. DNase hypersensitivity sites sequencing (DNase-seq) or 
ATAC-seq (Assay for Transposase-Accesible Chromatin sequencing)). But while 
these methods generate genome-wide regulatory profiles and chromatin states (Ernst 
et al. 2011), they have not lead to sequence-based enhancer models and usually 
contain high levels of non-functional noise.  
A key feature of TF binding is the presence of the TF’s DNA recognition sequence. 
Interestingly, sequence analysis on ChIP-seq data in yeast showed that not all 
identified peaks are directly bound by their TFs (Gordân et al. 2009). Similarly, 
amongst the hundreds of TF ChIP-seq data of ENCODE only a fraction of peaks were 
found to contain the canonical recognition sequence of their respective TF (Wang et 
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4 
al. 2012). But while a considerable amount of ChIP-seq peaks seem to be independent 
of the TF motif, it is not clear whether this indirect binding plays a functional role, i.e. 
whether it is involved in the regulation of a target gene. In Drosophila it has been 
suggested that indirect binding could be functional and contribute to gene regulation 
via transcription factor cooperative activity i.e. the tethering of a TF to an enhancer by 
other, directly bound factors (Junion et al. 2012). On the other hand, indirect binding 
could also reflect a technical aspect of ChIP and represent for instance fixation 
artifacts (Keren and Segal 2013; Waldminghaus and Skarstad 2010; Baranello et al. 
2015).  
Using the motif of the bound factor may be a good guide to identify functional 
binding, but for most – if not all - TFs, tens of thousands of recognition sequences, 
present throughout the genome, remain unoccupied or unbound. The current paradigm 
of how transcription factors discriminate between functional and non-functional 
locations is based on the combinatorial action of transcription factors. Here, binding 
specificity is achieved through clusters of binding motifs co-occurring within an 
enhancer (Stampfel et al. 2015; Maston et al. 2012; Shlyueva et al. 2014; Lee and 
Young 2013; Panne 2008), or by generating new recognition sequences for pairs of 
TFs . Such enhancers are generally classified under the enhanceosome or billboard 
models, depending on whether the order and spacing of motifs is important or not 
(Arnosti and Kulkarni 2005). Other local features in the DNA sequence of an 
enhancer have also been shown to contribute to the discrimination of bound versus 
unbound sites, such as GC content (White et al. 2013), preferential sequences for 
nucleosome positioning (Lidor Nili et al. 2010), DNA shape features (Chiu et al. 
2015) and dinucleotide repeat motifs (Yáñez-Cuna et al. 2014). However, to gain 
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5 
further insight into the cis-regulatory enhancer code and identify those that are truly 
bound and functional, validation assays are needed.  
The recent development of multiplex enhancer-reporter assays has been invaluable in 
procuring such information on a large scale. Whereas classically enhancer-reporter 
assays consist of cloning each enhancer one by one, first in vitro, later in vivo (Banerji 
et al. 1981; Chiocchetti et al. 1997; O’Kane and Gehring 1987; Dailey 2015), now 
hundreds to thousands of enhancers can be tested in parallel (Patwardhan et al. 2009; 
Arnold et al. 2013; White et al. 2013; Vanhille et al. 2015; Patwardhan et al. 2012; 
Kheradpour et al. 2013; Smith et al. 2013; Melnikov et al. 2012; Kwasnieski et al. 
2012). These methods can be broadly categorized in two groups, namely massively 
parallel reporter assays (MPRA) utilizing barcodes as a measure of activity of 
synthesized enhancer fragments (Kheradpour et al. 2013; Patwardhan et al. 2009, 
2012; Smith et al. 2013; Melnikov et al. 2012; Kwasnieski et al. 2012; White et al. 
2013)), and self-transcribing active regulatory region sequencing (STARR-seq) 
(Arnold et al. 2013; Vanhille et al. 2015). 
 
In this work we unravel the genome-wide binding profile of TP53 (protein product of 
TP53, also known as p53), addressing these two questions simultaneously by 
investigating (i) the differences between direct and indirect binding and (ii) the 
differences between bound and unbound recognition sequences in the genome. TP53 
is a tumor-suppressor that regulates its target genes in response to different stimuli 
like DNA damage or cellular stress, eliciting functions like growth arrest or apoptosis 
(Vousden and Prives 2009). Its importance is moreover reflected by the fact that TP53 
is the most commonly mutated gene found in cancer (Muller and Vousden 2014). 
Although much research has gone in understanding how and where TP53 interacts 
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with DNA, many questions and contradictions remain. For instance, it is unclear what 
the functional role is of indirect binding of TP53 to the DNA (Kirschner et al. 2015), 
whether TP53 also directly represses genes (Ho and Benchimol 2003; Johnson et al. 
2001; Rinn and Huarte 2011) and how TP53 elicits different responses like apoptosis 
and growth arrest, activating different genes for each process (Smeenk et al. 2008; 
Menendez et al. 2013). Several elements of the TP53 binding site architecture have 
been proposed to contribute to the functional properties of the enhancer. These 
include variations of the spacer between two TP53 half-sites (Godar et al. 2008; 
Hoffman et al. 2002), or variations in binding sites for co-regulatory factors 
(Thornborrow and Manfredi 2001; Koutsodontis et al. 2001). However, these 
properties have not been evaluated on a global scale. To resolve these uncertainties 
and to generate a global TP53 enhancer model, we have combined two types of 
multiplex enhancer-reporter assays followed by machine learning. Our results yield a 
new unsophisticated model for TP53-mediated transcriptional regulation and allow us 
to create a ranked list of all potentially functional TP53 binding sites in the human 
genome. 
 
Results 
Quantitative enhancer-reporter activity for hundreds of enhancers in parallel  
We developed a new method, called CHEQ-seq (Captured High-Throughput 
Enhancer testing by Quantitative sequencing) to test enhancer-reporter activities for 
hundreds of enhancers simultaneously (Fig. 1a). Although conceptually CHEQ-seq is 
similar to the recently published capture-and-clone variant of CRE-seq (Shen et al. 
2015; Kwasnieski et al. 2012), CHEQ-seq uses a different cloning and sequencing 
strategy (Supplemental protocol). Firstly, candidate enhancers from sheared 
 Cold Spring Harbor Laboratory Press on June 20, 2016 - Published by genome.cshlp.orgDownloaded from 
  
 
  
 
7 
genomic DNA are captured using custom designed baits (Fig. 1a, Supplemental Fig. 
S1a). These enriched DNA fragments, averaging 500 base pairs, are then cloned 
upstream of a fluorescent protein reporter preceded by a minimal promoter and a 
synthetic intron (Arnold et al. 2013) and followed by a 17 base pair random barcode 
allowing for 17x109 possible barcodes (see Methods). Using CHEQ-seq we tested the 
enhancer activity of 1,526 TP53 ChIP-seq peaks obtained in MCF7 breast cancer cells 
treated with Nutlin-3a (Janky et al. 2014). Additionally, 94 promoters of 
housekeeping genes (HKG) were selected as control regions assuming that they drive 
stable reporter gene expression independent of any perturbation (Eisenberg and 
Levanon 2013). Also, 66 negative control regions in the genome were selected (see 
Methods, (Yip et al. 2012)). Unique to CHEQ-seq is long-read sequencing of the 
entire library to resolve the randomly formed enhancer-barcode pairs which after 
processing and removing redundancy yielded 20,751 distinct genomic fragments 
linked to 24,906 different barcodes (Methods and Supplemental Fig. S1b, S2).  
To test which candidate enhancers are TP53-responsive, we transfected the enhancer-
reporter library into MCF7 cells treated with Nutlin-3a, activating TP53 (p53-high) or 
containing a stable shRNA knock down for TP53 (p53-off) (Phillips et al. 2010) 
(Supplemental Fig. S1a). Reporter activity levels were determined by counting 
sequencing reads of barcoded cDNAs and were normalized both by the input library 
and by the re-extracted plasmid DNA (Methods and Supplemental Fig. S3). Of all 
the barcodes linked to a genomic fragment, we could measure 21,182 distinct 
barcodes representing 18,399 unique genomic fragments, of which 22.8% overlapped 
with the designed regions (81428-fold enrichment) (Supplemental Table S1, 
Supplemental Fig. S1c).  
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We performed several quality control steps to assess whether the barcode expression 
represent accurate enhancer-reporter levels. Firstly, independent biological replicates 
show a very high correlation amongst barcodes within the p53-high condition (r2 = 
0.99). The correlation of the p53-off condition is much lower, as expected, since the 
majority of enhancers are inactive in the p53-off condition (r2 = 0.56). The induced 
activity, measured as the fold-change between p53-high and p53-off also correlates 
between the two biological replicates (r2 = 0.72) (Supplemental Fig. S4). Secondly, 
the expression levels of two different barcodes linked to the same enhancer region 
showed strong correlation of the fold-changes between p53-high and p53-off (r2 = 
0.73). Thirdly, different regions that overlap with the same designed region also show 
strong correlation (r2 = 0.72) (Supplemental Fig. S5). Finally, the CHEQ-seq 
enhancer-reporter differential expression values are recapitulated when performing 
classical enhancer-luciferase assays (Fig. S1b-f). These validation experiments 
confirm that the expression measured by CHEQ-seq are reliable and reproducible. 
Overall, CHEQ-seq allows cloning of hundreds of predefined enhancers into a 
complex barcoded library and generates reliable and reproducible reporter expression 
representing the functionality of a subset of these enhancers.  
 
Only 40% of TP53 ChIP-seq peaks are functional enhancers 
Having established CHEQ-seq as an accurate multiplex enhancer-reporter assay we 
turned to all the tested regions covering TP53 ChIP-seq peaks. Of the 1,526 targeted 
peaks, 1010 (66%) were represented by at least one captured sequence and non-
ambiguous barcode. An additional 49 peaks were covered by randomly captured 
sequences. Of the 859 peaks that were covered sufficiently (Fig. S2a) (60% overlap, 
see Supplemental Fig. S6, S7), only 350 (40.7%) are significantly higher in p53-high 
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compared to p53-off conditions (called “positives”, adj. p-val < 0.05 and log2FC >= 
1.5, (see Methods)). Interestingly, TP53 does not seem to directly repress enhancers 
since only ten peaks show significant down-regulation upon TP53 activation (down, 
adj. p-val < 0.05 and log2FC =< -1.5). Of the remaining ChIP-seq peaks, 337 are 
TP53-unresponsive (negatives), while another 162 show borderline expression 
patterns (greyzone) (Fig. 2a, Supplemental Table S2). Note that within the 
promoters of HKG, negative regions or non-specifically captured regions almost no 
TP53 inducible enhancers are found (0.95%, of HKG and negative controls and 1.6% 
of non-specific regions) (Supplemental Fig. S6, S8).  
Next we compared the barcode reporter activity levels measured by CHEQ-seq to the 
existing multiplex enhancer-reporter method STARR-seq (Arnold et al. 2013), using 
the same captured fragments and the same transfection conditions (Supplemental 
Fig. S9-S10, Supplemental Table S3). The main difference in STARR-seq is that the 
tested regions are inserted at the 3’ of the transcription start site, causing the 
enhancers to transcribe themselves rather than relying on barcodes. STARR-seq 
yields reproducible expression values for 975 peaks, of which 242 peaks are TP53 
responsive, 463 peaks as non-responsive and 216 peaks as greyzone (Supplemental 
Fig. S11, Supplemental Table S4). The slightly smaller number of TP53 responsive 
elements compared to CHEQ-seq may possibly be due to differences in location of 
the enhancer regions within the reporter construct. STARR-seq also confirms that 
only very few ChIP-peaks (45 peaks) are repressed, and that the control groups do not 
show TP53-dependent changes (Supplemental Fig. S12). In total 600 ChIP-seq peaks 
have reporter activity data from both the CHEQ-seq and STARR-seq method. When 
looking at the subsets created independently for each method we see a highly 
significant overlap, with 190 out of 231 CHEQ-seq positives being labeled as 
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positives or greyzone in STARR-Seq (82.3%, chi-square p-value = 1.24 10-26) (Fig. 
2b-c). Interestingly, the small number of down-regulated ChIP-seq peaks identified by 
either method was not validated by the other method, suggesting that these were 
mainly false positives and that TP53 exclusively activates gene expression. In 
conclusion, multiplex enhancer reporter assays provide reproducible sets of direct 
TP53 enhancers and reveal that a relatively small subset of ChIP-seq peaks act as 
enhancers.  
 
Unsophisticated TP53 enhancer logic  
Using CHEQ-seq we discriminated true positive TP53 target enhancers from 
unresponsive yet TP53-bound regions. As these regions are all tested in the same 
episomal reporter environment, the enhancer-determining information should be 
contained within the DNA sequence. To compare the sequences between both sets we 
employed three motif discovery tools, namely i-cisTarget (Imrichová et al. 2015), 
RSAT peak motifs (Thomas-Chollier et al. 2011) and HOMER (Heinz et al. 2010), 
allowing for de novo motif discovery as well as enrichment of known motifs, using 
libraries of position weight matrices (PWM). All tools identified the TP53 motif as 
most over-represented in the TP53-responsive sequences, with highly significant p-
values (HOMER p-values <= 10-322, RSAT significance value = 72.30, i-cisTarget 
NES > 28). Note that, while some other motifs were found marginally 
overrepresented, these findings were not consistent across tools, were enriched at 
much lower p-values and occurred in a limited number of the positive regions 
(maximally 25%) (Supplemental Fig. S13-S15). This suggests that TP53 mainly 
functions alone, without other regulatory factors co-binding at the DNA level. This is 
surprising as one of the proposed mechanisms for TP53 target specificity is through 
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the recruitment of co-regulatory transcription factors (Thornborrow and Manfredi 
2001; Koutsodontis et al. 2001). 
Previous reports indicate that small differences in the motif composition can influence 
binding affinity and determine target specificity (Godar et al. 2008; Inga et al. 2002; 
Wei et al. 2006; Smeenk et al. 2008). We therefore tested whether individual motifs, 
differing slightly from one another, perform differently in identifying true targets. We 
selected the ten best TP53 motifs based on their significance and low occurrence in 
the negative set. These ten motifs differ in length and composition but all retain the 
essential double C/G core of the TP53 binding site  (Fig. 3a). When plotting the 
maximum score of each motif for both the positive and negative sets, the TP53 motif 
strongly distinguishes the sets with a marked absence of motifs amongst the non-
responsive regions (Fig. 3b). Only 45 out of 687 peaks were misclassified by CHEQ-
seq, likely representing technical limitations of the experimental method itself. 
Indeed, the CHEQ-seq negatives that do have a TP53 motif are often identified as 
positive in STARR-seq (4 out of the 6). Vice versa, CHEQ-seq positives without 
TP53 binding site are often not identified as positive by STARR-seq (only 6 of the 
17). Note that almost no down-regulated enhancers, identified by CHEQ-seq score for 
a TP53 motif (Supplemental Fig. S16).  
The classification performance of these motifs, and combinations thereof can be 
assessed using a Receiver Operating Characteristic (ROC) (Fig. 3c-e). Overall the 
performance for the different motifs is very comparable, with multiple motifs yielding 
an area under the ROC curve (AUC) above 0.95. A 2-fold cross validation at the level 
of feature selection (i.e. de novo motifs) ensured that these models are not over-fitted 
(see Methods, Supplemental Fig. S17). Interestingly, accurate TP53 binding site 
prediction requires the full PWM of the TP53 tetramer, as one half-site alone has a 
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poor predictive performance (AUC = 0.81). In addition, and contrary to previous 
reports (Riley et al. 2008; Cook et al. 1995; Tokino et al. 1994), all TP53 motifs, both 
de novo and known, have no gap between the two half sites. As each of the individual 
motifs has a slightly different nucleotide composition flanking the C/G quadruple, we 
wondered whether scoring with a combination of all motifs would improve the 
predictive power (Fig. 3f). Surprisingly this was not the case as the combination of all 
motifs had the same predictive power as the best-scoring motif (AUC = 0.98). This 
suggests that the nucleotide composition of the TP53 motif can be largely captured by 
a single optimal PWM. Next, we tested whether homotypic clusters of TP53 sites 
were characteristic for TP53 responsiveness. Although previously suggested 
(Bourdon et al. 1997), our data suggests that a single TP53 site is sufficient to 
distinguish TP53-responsive from non-responsive enhancers (Fig. 3f-g). Although the 
presence of a TP53 binding site is predictive of enhancer activity, the strength of the 
binding site is not indicative of the quantitative levels of reporter, suggesting a binary 
on/off state of a TP53 enhancer (Fig. 3h). This is further confirmed by comparing the 
quantitative enhancer-reporter levels with the height of the ChIP-seq peak score, 
which also does not correlate beyond the on/off categories (Fig. 3i, Supplemental 
Fig. S16, S18). In conclusion, TP53 enhancers are unsophisticated in their 
architecture with the presence of a single TP53 binding site containing a double C/G 
core that is both necessary and sufficient to actively drive expression in a binary 
fashion.  
 
Indirect ChIP-seq peaks have no regulatory function 
The ChIP-seq peaks that were not directly bound by TP53 through a TP53 binding 
site showed no increased enhancer-reporter activity, nor any basal level of enhancer 
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activity in the reporter assay (Fig. 4a). To test whether indirect peaks may have 
another regulatory function, we first predicted which ChIP-seq peaks within the full 
set of 3634 TP53 ChIP-seq peaks (Janky et al. 2014) are likely directly bound based 
on the presence of a TP53 motif. To this end, we used a Random Forest model trained 
on the CHEQ-seq positive set, with the nine TP53 PWMs identified above 
(Supplemental Fig. S19). This classifier predicted 671 direct and 2963 indirect 
peaks. To investigate whether the indirect peaks could work as enhancers in their 
endogenous genomic context, we performed ChIP-seq against H3K27ac under the 
same conditions. These data confirm that only the directly bound peaks are enhancers 
with H3K27ac marks (Fig. 4b).  From this figure, it can also be seen that the direct 
peaks are overall higher and wider than the indirect peaks, although the distributions 
overlap with each other (Fig. 4b, Supplemental Fig. S20). Additionally, while the 
directly bound regions show increased chromatin accessibility upon TP53 activation, 
this is not the case for indirectly bound regions (DNase-seq data under similar 
conditions (The ENCODE Project Consortium 2012; Thurman et al. 2012)) 
(Supplemental Fig. S21). Furthermore, whereas the direct peaks are located near 
TP53 target genes, as determined by gene annotation or by up-regulated gene 
expression, the indirect peaks are not enriched near putative target genes, and are 
often found to overlap coding exons (Fig. 4c, Supplemental Fig. S22, S23 and 
Supplemental Table S5, S6). Finally, direct peaks significantly overlap with long 
terminal repeats (LTRs), indirect peaks do not (Supplemental Fig. S24).  
None of the above tested features suggest that the negative indirect peaks have a 
regulatory function. We therefore considered the possibility that they could represent 
crosslinking artifacts (Keren and Segal 2013; Waldminghaus and Skarstad 2010; 
Baranello et al. 2015). If so, then these artifacts should not be reproducible across 
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different experimental conditions. To test this, we turned to other publicly available 
datasets and collected 15 different TP53 ChIP-seq experiments performed in 7 
different cell lines under different TP53-stimulating conditions (Supplemental Table 
S7) (Desantis et al. 2015; Botcheva and McCorkle 2014; Smeenk et al. 2011; 
Nikulenkov et al. 2012; Sammons et al. 2015; McDade et al. 2014; Hünten et al. 
2015; Zeron-Medina et al. 2013; Sánchez et al. 2014). After calling peaks for each 
experiment, we categorized all peaks in each dataset as direct or indirect using the 
Random Forest model. Whereas the total number of peaks differs greatly between 
data sets, this difference can be mainly attributed to differences in the number of 
indirect peaks (Fig. 4d). Remarkably, in contrast to the direct peaks that are strongly 
conserved between experiments, the indirect peaks are largely unique to each data set 
(Fig. S4e, Supplemental Fig. S25), strongly suggesting a non-functional role. In 
conclusion, the presence of an unsophisticated TP53 binding model is predictive of 
functional enhancers amongst ChIP peaks, while remaining peaks have no obvious 
regulatory function and may represent crosslinking artifacts. 
 
Genome-wide TP53 responsive enhancers are invariably used across cell types  
Unsophisticated enhancer logic, with only a single high-scoring TP53 binding site 
being necessary and sufficient for a TP53 responsive enhancer, would predict 
invariable genomic binding across different cell types and experimental conditions. 
This simple model would thus contradict previous reports that proposed a direct role 
for TP53 binding sites and enhancers in differentially regulating cell-type dependent 
activation of its targets. To address this, we decided to test our simple model on a 
genomic scale and across cell types and treatment conditions. We first applied our 
previously trained Random Forest model on the entire human genome and predicted 
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21659 potential TP53 responsive enhancers. We then plotted the ChIP-seq signal 
across all publicly available datasets for all these binding sites. After testing several 
different clustering parameters, we found that the average coverage across binding 
sites within each generated cluster always converged onto three robust clusters (see 
Methods, Supplemental Fig. S26). A first cluster (strongly bound) with 1148 sites is 
preferentially bound by TP53 across all datasets. A second cluster (weakly bound), 
with 3147 sites is also shared across data sets, but with significantly lower binding 
signal. Finally, a third cluster with the remaining 17364 sites show no binding across 
the datasets (Fig. 5). This finding suggest that TP53 binds only a limited number of 
sites throughout the genome and that, importantly, in contrast to earlier reports, these 
sites are highly conserved across different experimental conditions and cell types 
(Supplemental Fig. S27). 
 
Sequence context and DNA shape of TP53 responsive enhancers are different, 
but not predictive  
To explain why TP53 preferentially binds to only a small subset (19.8%) of all the 
genome-wide predicted binding sites, and to improve our predictive model, we 
investigated several local characteristics of the enhancer itself, including the sequence 
constraint across species, the strength of the TP53 motif, dinucleotide composition 
and the DNA shape flanking the motif. Additionally we investigated several 
characteristics of the genomic locus outside the enhancers, such as the presence of a 
nearby TATA or CpG promoter. Including these properties outside the enhancer is 
inspired by the possibility that binding of TP53 could perhaps be stabilized when it 
results in an effective target gene regulation, resulting in longer and thus higher 
frequency binding across cells in culture. In support of the three clusters (strong-
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weak-unbound), we found that sequence constraint across vertebrate genomes is much 
higher for the strongly bound sites than for the weakly and unbound sites, 
corroborating their functional role (Fig. 6a). Note that we decided not to incorporate 
this feature into our predictive model because it is not a primary feature of the 
genome. We compared all other features, both local and global, by including them one 
by one, and in combinations, as features into our Random Forest classifier. 
Surprisingly, only the TP53 PWMs contributed significantly to the performance. In 
other words, the TP53 motif not only allows distinguishing direct from indirect ChIP-
seq peaks (see above), but also further discriminates strongly bound sites from 
unbound sites in the genome (AUC=0.87, blue curve Fig. 6b). When investigating the 
feature importance in the Random Forest model, we found the TRANSFAC motifs 
M01655 and M01656 to have the highest weights (Supplemental Fig. S28). The poor 
predictive performance of the other sequence features is surprising because on 
average many of these features show distinct patterns between the strongly bound and 
unbound sites. For example, functional TP53 sites show a drop in the occurrence of 
A/T dinucleotide sequences (TT, AA, TA, and AT), around 100 bp on each side of the 
binding site (Fig. 6c-d). Secondly, the strongly bound sites differ from unbound sites 
in DNA shape properties like propeller twist, helical twist and GC content, again 
around 100 bp each side of the binding site (Fig. 6f-h). Note that the weakly bound 
sites have an intermediate profile, having values for these features halfway between 
the strong and unbound site. This suggests that this cluster should indeed be 
considered as a separate group within the TP53 binding sites. To test whether 
additional unknown sequence features could play a role in determining strongly 
bound TP53 enhancers, we also trained a deep learning model directly on the bound 
versus unbound sequences, which automatically learns discriminative features (see 
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Methods). The classification performance is comparable to the random forest model 
using TP53 PWMs, which suggests that no additional features could be identified 
(Fig. 6b, yellow curve). In conclusion, a key role is played by the TP53 motif in 
defining functional binding, while other features contribute only marginally to the 
binding specificity.  
 
Strength of binding site predicts quantitative TP53 binding 
While the strongly bound and unbound clusters are clearly separated in their ability to 
bind TP53, the weakly bound sites exhibit intermediary characteristics. To avoid the 
arbitrary cut-offs of the clustering we instead ranked all the 21659 sites using the 
ChIP-seq coverage across each experiment, followed by a rank aggregation step 
yielding a final meta-ranking (see Methods). This meta-ranking strongly recapitulates 
the three clusters from above (Fig. 7). Interestingly, the ChIP-seq signals are 
quantitatively comparable between different experiments. Furthermore, decreasing 
ChIP-seq signals are strongly correlated with decreasing probability of TP53 binding 
both by the Random Forest and the Deep Learning models (Fig. 7a, black and purple 
curves). The ranked list is also correlated with the functionality, as shown by 
correlating H3K27ac signal, DNase-seq and GRO-seq data. This observation provides 
additional confirmation that the regions are ranked in decreasing functionality (Fig. 
7a). Note that many of the weakly bound sites also show increased chromatin 
accessibility, which is expected when TP53 binds and displaces nucleosomes, but 
they have significantly less H3K27ac and GRO-seq marks (Su et al. 2015; Sammons 
et al. 2015). This functional difference is furthermore corroborated by the fact that 
genes located near highly ranked sites are located near TP53 related genes, while 
lower ranked sites show no Gene Ontology or pathway enrichment for TP53-related 
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processes (Supplemental Table S8-S9). Nevertheless, weakly bound sites can 
function as enhancers, since 49% of weakly bound sites is positive in the CHEQ-seq 
or STARR-seq assay, compared to nearly 80% of the strong sites driving gene 
expression in the context of a reporter assay (Fig. 7c and Supplemental Fig. S29, 
S30). Taken together, these results suggest that functionality is predictable by the 
sequence, and decreases gradually by the strength of the TP53 binding site.  
 
Discussion 
The functional annotation of all regulatory elements in the non-coding part of the 
human genome is a key challenge in genome biology. Although biochemical events 
such as protein binding to the DNA occur very frequently, and such events cover 
more than 80% of the genome (The ENCODE Project Consortium 2012), only a 
fraction of these binding events is expected to be functional (Carvunis et al. 2015). In 
the context of the presented work, we consider a genomic region to be functional if it 
contributes in a deterministic and observable fashion to the regulation of gene 
expression. In our study, we found that among the 95077 observed binding events for 
TP53, across sixteen data sets covering diverse cell types and conditions, and among 
the more than 20,000 possible TP53 recognition sites in the genome, only a small 
fraction are bona fide TP53 responsive enhancers. Rather than deciding on a cut-off, 
we generated a ranking of all candidate sites based on the combination of the 
aggregated binding data and found that this meta-ranking correlates strongly with the 
strength of the TP53 binding site. This correlation can already be observed with a 
high-quality position weight matrix (PWM), but is even stronger for a trained 
classifier based on multiple PWMs or a deep learning model trained directly on 
strongly bound enhancer sequences. We provide a hub at the UCSC Genome 
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Browser, containing genome-wide binding across experiments and the scores for the 
model predictions (see Methods). This TP53 hub can serve as a reference for TP53-
related future studies. Indeed, we argue that the observed consistency of direct TP53 
binding across experimental conditions is so high that our ranking can be a good 
guide for the putative functionality of a given TP53 site, regardless of the 
experimental conditions. Note that the models presented here are derived from data 
sets after inducing TP53 in cell culture, both in cancer and normal cell lines. The 
question whether this unsophisticated enhancer model for TP53 also applies to other 
TP53-related functions, for example during in vivo development, remains to be 
investigated.   
 
Only a small, yet predictable subset of experimentally determined binding events 
represent TP53 responsive elements. The other binding events (up to >90%, 
depending on the data set, see Fig. 4f) are presumable the result of cross-linking 
artifacts or other technical aspects of the ChIP method or its analysis. Similar 
observations have been made before, where binding of a transcription factor to the 
DNA can occur either due to the presence of its motif, when the binding is functional, 
or independently of the motif, when the binding is not functional. For example, Kvon 
et al. found that Twist is often bound to HOT regions in Drosophila, but only the 
binding in the mesoderm at the right time point, when Twist is actually expressed, 
corresponded to motif-dependent direct binding sites (Kvon et al. 2012).  
 
In this study we have learned several new things about TP53. Firstly, our data 
supports the most common model for TP53 binding, namely that TP53 binds the 
DNA strictly as a tetramer, to a duplicate of the consensus palindromic responsive 
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element RRRCWWGYYY (R = purine; W = adenine/thymine; Y = pyrimidine), 
separated by a spacer of length N = 0, and not to single half-sites. Whereas previous 
reports argued that the sequence composition of the TP53 binding site may play a role 
in explaining context-dependent activation (Beckerman and Prives 2010; Weinberg et 
al. 2005; Szak et al. 2001), our results are consistent with other studies that reject this 
hypothesis  (Smeenk et al. 2008; Wei et al. 2006). Another clear result from our 
experiments is that TP53 can only directly activate enhancers and in contrast to 
previous reports (Godar et al. 2008; Hoffman et al. 2002), we find no evidence of 
direct repression. Another intriguing finding is that TP53 seems to bind to chromatin 
independently of pre-existing nucleosome accessibility. For this we confirm earlier 
studies (Lidor Nili et al. 2010; Cui et al. 2011; Su et al. 2015). This finding supports 
the clutch-like model whereby transcription factors are able to displace nucleosomes, 
and are in competition with nucleosome binding. Finally we find that TP53 mostly 
acts alone as a TF bound to its target enhancers, although previous studies had 
suggested co-factorship at the DNA level (Thornborrow and Manfredi 2001; 
Koutsodontis et al. 2001). Note that non sequence-specific co-factors (e.g. P300) are 
likely to interact with TP53 at the protein level, independent of the DNA sequence, to 
recruit RNA polymerase and activate target gene transcription.  
 
Enhancer sequences have recently been shown to share characteristic features beyond 
transcription factor binding sites, such as a particular distribution of Cs, Gs, and CpGs  
(Kwasnieski et al. 2012) or the presence of dinucleotide repeat motifs, such as CA, 
GA or CG (Yáñez-Cuna et al. 2014). The flanking nucleotides of our TP53 responsive 
elements also show an intriguing bias in nucleotide composition, which likely 
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represent preferential nucleosome binding positions. Although these patterns are 
clearly visible at the global level, these features do not have predictive power.   
 
Among the ~21,000 potential TP53 binding sites, we find ~1000 regions that are 
strongly bound and represent bona fide responsive elements, regulating target gene 
expression, as effectors of the TP53 response. In addition, another subset of around 
~3,000 sites show weak TP53 binding. This set is much less related to enhancer 
activity, gene expression, or nearby gene function. On the other hand, the recognition 
sites are more conserved in evolution and they have stronger PWM matches than the 
unbound. It is intriguing to speculate what the function of these sites could be. One 
possibility is that these sites could be preferentially bound when there is an excess of 
TP53 protein. Indeed, from a statistical point of view, given that TFs need “time” to 
find their functional binding sites, a cell needs to produce an excess of functional 
transcription factors to ensure that the entire functional cistrome remains occupied. 
Thus, at all times a fraction of molecules is undergoing fast binding turnover at non-
functional sites (also called treadmilling (Lickwar et al. 2012)) where they become 
fixated during the ChIP protocol. Interestingly, we find that a quantitative relationship 
between prolonged residence and the strength of the TP53 binding site, rather than 
other additional sequence features. This idea adheres to the recently proposed clutch-
like model of transcription factor binding (Lickwar et al. 2012). 
 
Achieving high-confidence predictions at the genome-wide scale requires machine 
learning classifiers that are trained on large sets of positive and negative enhancer 
sequences. We, and others before us, have shown that massively parallel enhancer 
reporter assays can relatively quickly lead to such training sets, and usually lead to 
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exciting new insight into the cis-regulatory logic of enhancers (Arnold et al. 2013; 
Kwasnieski et al. 2012; White et al. 2013; Kheradpour et al. 2013; Melnikov et al. 
2012). In our study we have tested long enhancer sequences, of several hundreds of 
base pairs. Earlier methods for massively parallel enhancer reporter assays (MPRA) 
often relied on oligonucleotide synthesis to generate sequences, thereby limiting the 
fragment size considerably below that of an average metazoan enhancer (~200 bp 
(LeProust et al. 2010) as compared to ~500-800 bp). This issue has recently been 
overcome by cloning captured fragments into a barcoded reporter assay (Shen et al. 
2015). In addition, the STARR-seq method bypasses the issue of short input 
fragments by inserting randomly fragmented regions of the genome straight into a 
library downstream of a reporter gene rather than upstream (Arnold et al. 2013). 
STARR-seq was originally developed for Drosophila, where the genome size is 
manageable to clone in its entirety. However, considering that the human genome is 
25 times larger, it presents a considerable challenge towards genome-wide assays. A 
solution to this is to preselect the input, as has been done in our study here, as well as 
recently in mice, using a STARR-seq like approach, called CapStarr-seq (Vanhille et 
al. 2015). The possibilities that these methodologies provide with regards to enhancer 
validation, both in vitro and in vivo (White et al. 2013; Shen et al. 2015), underscores 
the value and the need for such approaches in the field of regulatory genomics today.  
 
Our case study of TP53 may seem peculiar in the sense that TP53 acts in isolation, 
without co-regulatory transcription factors that bind to the same enhancer. Although 
this was quite an unexpected finding, in retrospect this observation fits well within the 
cell-autonomous function of TP53. Indeed, upon DNA damage TP53 activates the 
appropriate target genes to either repair the damage, or launch the apoptotic program 
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(Beckerman and Prives 2010). Although we now have a better understanding of the 
TP53 “cistrome”, it remains to be discovered how generic activation of the same set 
of enhancers is differentially steered in the currently operational gene regulatory 
network, and how the cellular context further contributes to the resulting responses 
like apoptosis or growth arrest.   
 
The unsophisticated enhancer model, with only a single TP53 binding site, is to our 
knowledge the first report of such a new class of enhancers in the human genome. 
Previously, such enhancer models were used for compact genomes from bacteria, or 
sometimes yeast, but not for multicellular organisms. Plant and metazoan enhancers 
are usually classified as enhanceosome or billboard model (Arnosti and Kulkarni 
2005), but these types of models are based on the combinatorial action of multiple 
transcription factors to reach specificity. Whereas developmental enhancers need to 
integrate multiple signals and environmental queues (e.g., signaling gradients), each 
cell can be considered independently responsible for its own genome integrity. Such a 
model may be valid for additional cell-autonomous factors, such as the cell-cycle 
related factors of the E2F family. Thus, we consider the TP53 enhancer model to 
represent a new class of unsophisticated, single-factor metazoan enhancers.  
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Material and methods 
CHEQ-seq plasmid and bait design 
A super core promoter, a synthetic intron (Arnold et al. 2013) and a venus reporter gene 
(Roure et al. 2007) were inserted between the in the KpnI and XbaI restriction sites of the 
pGL4.23 plasmid (Promega cat No E8411). Barcodes were incorporated using a inverse PCR 
into the modified pGL4.23 backbone with AscI (see supplemental materials). 120 ng of 
plasmid was electroporated per 20 µl of electrocompetent cells (Invitrogen, cat No C6400-03) 
and extracted using a Giga prep (Qiagen no. 12191). ChIP-seq peaks for TP53 were called 
against input (GSE47043) as described before (Janky et al. 2014) and were filtered for 
centromere and telomere regions and ranked based on their peak score. The top 1700 regions 
were selected for bait design as described in supplemental Materials and Methods. 
 
Generating the CHEQ-seq and STARR-seq libraries 
Genomic DNA was extracted, adapter ligated and amplified. Targeted regions were captured 
with the MYbaits protocol (Custom bait libraries, MYcroarray). At least three captures were 
performed and pooled after purification. The CHEQ-seq plasmid containing the barcode pool 
was linearized and combined with ~250 ng input DNA in a total of 4 infusion reactions 
(Clontech). The recombined library was precipitated overnight and transformed at 100 ng per 
20 µl electrocompetent cells. See supplemental Materials and Methods for additional details. 
 
Cell work and extractions 
MCF7 cells (TP53 wild type or TP53 knock down) were cultured and transfected as described 
before (Janky et al. 2014). DNA and RNA was extracted and cDNA prepared according to the 
manufacturer’s guidelines. See Supplemental Materials and Methods for more details. 
 
Library preparations  
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cDNA or (extracted) plasmid DNA was amplified with two rounds of PCR using the Phusion 
High-fidelity PCR master mix (cat no M0532S, PCR details in Supplemental Materials and 
Methods). The library was purified using the AMPure XP Beads (Beckman Coulter, cat no 
A63880) and sequenced on the Illumina HiSeq2500 platform. For STARR-seq the DNA and 
cDNA libraries were created as described before (Arnold et al. 2013). For PacBio sequencing, 
the input library was amplified using the Phusion High-fidelity PCR master mix (cat no 
M0532S, PCR details in supplemental Materials and Methods). The linear fragments of 
around 2-3 kb were purified using AMPure XP Beads (Beckman Coulter, cat no A63880). 
Libraries were subsequently sent for SMRT PacBio sequencing (Pacific Biosciences).  
Data processing and subset determination for both CHEQ-seq and STARR-seq libraries are 
described in Supplemental Materials and Methods. 
 
Motif discovery and motif scoring 
HOMER (Heinz et al. 2010) and RSAT peak motifs (Thomas-Chollier et al. 2011) were run 
on the positive set with the negative set as background. i-cisTarget (Imrichová et al. 2015) 
was run on the positive set. For HOMER, length of the motif was set at length 19 or 20 (-len) 
to allow for discovery of the consensus TP53 motif in the de novo option. Motifs were 
selected based on their overall performance and low occurrence in the negative set (see 
supplemental Materials and Methods). For each obtained motif or the combination of all 10 
motifs Cluster-Buster (Frith et al. 2003) was used to score the positive and negative sets using 
–c 0 and –m 0. The highest motif score (or CRM score) for each region was obtained and 
used to determine the predictive value of each motif to classify regions into positives or 
negatives. In short, the sensitivity and specificity for each motif was calculated and the area 
under the receiver operating characteristic curve (AUC) determined. 
   
ChIP-seq, RNA-seq and public data 
ChIP-seq against H3K27ac was performed and analyzed as described before (Verfaillie et al. 
2015). RNA-seq for MCF7 TP53 knock down was extracted and performed as described 
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previously (Janky et al. 2014). The collected public ChIP-seq data against TP53 are 
summarized in Supplemental Table S7. See supplemental Materials and Methods for a more 
extended methodology and processing of the data. 
 
Random Forest model and Feature-vector representation  
Different Random Forest models were generated (see supplemental Materials and Methods). 
As Random Forest implementation we used the scikit-learn Python package. Each classifier 
uses an ensemble of 151 decision trees. The parameter max_features (responsible for number 
of features to consider when looking for the best split) was set to sqrt (number of features). To 
calculate the feature importance we used the Gini impurity criterion averaged across trees, 
using the whole training data. The quality of each model was estimated in 5-fold cross-
validations. For each PWM the motif score was calculated employing a Hidden Markov 
Model as implemented in Cluster-Buster (Frith et al. 2003). Number of coding genes and 
lncRNAs was calculated using bedTools and a custom bash script. The file with TSSs of 
genes was downloaded from the UCSC Genome Browser. High confident subsets of lncRNAs 
were downloaded from LNCipedia (Volders et al. 2015). Files with the positions of promoters 
with TATA-box and/or GpC islands have been downloaded from the FANTOM5 resource 
(Lizio et al. 2015, 5).  
 
seqMINER, clustering and DNA shape 
BAM files of all public data (15 samples) and in-house data (see GSE47043) were loaded into 
seqMINER (Ye et al. 2011). A BED file with all predicted TP53 binding sites was loaded. 
Alternatively in-house TP53 ChIP-seq data, H3K27ac or DNase-seq BAM files were loaded 
and compared across the positive and negative CHEQ-seq peaks. The flanking area was set at 
2000 bp around the binding site. Heatmaps show the raw tag count coverage from each BAM 
file for each input site or peak. Determination of clustering is described in supplemental 
Materials and Methods (Supplemental Fig. S26).  DNA shape data indicating Helix Twist 
(HelT) and Propellor Twist (ProT) for HG19 were downloaded from 
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ftp://rohslab.usc.edu/hg19/ in bigWig format (Chiu et al. 2015) and analyzed as described in 
supplemental Materials and Methods. 
 
Prediction of TP53 binding using Deep Learning 
The network was trained using the RMSprop algorithm for Stochastic Gradient Descent with 
100 training samples in each mini-batch and binary cross-entropy loss function for 
minimization. the Keras 0.2.0 library (https://github.com/fchollet/keras) with the Theano 0.7.1 
backend was used for implementation. Calculations have been performed with NVIDIA K40c 
accelerator. The regularization parameters are: dropout proportion (fraction of outputs 
randomly set to 0) for layer 2: 10%; layer 3: 10%; layer 6: 50%; all other layers: 0%. The 
details of the CNN model architecture are listed in Supplemental Materials and Methods. 
 
Additional information 
Data access 
Data generated for this study have been submitted to NCBI Gene Expression Omnibus  
 (GEO, https://www.ncbi.nlm.nih.gov/geo/) under accession number GSE76657.  
The predicted genome-wide TP53 binding sites and combined ChIP-seq data from all 
experiments used in this work are available as a track hub 
(http://ucsctracks.aertslab.org/p53/hub.txt). To activate this track hub, go to My Data, Track 
hubs in the UCSC Genome Browser menu, and provide this URL in “My Hubs”.    
 
Acknowledgments  
We thank Alexander Stark for providing the STARR-seq plasmid, for advice on the execution 
of the STARR-seq protocol, and for helpful discussions. We also thank Jean-Christophe 
Marine and Jonas Demeulemeester for helpful discussions and advice on the manuscript. 
 
Funding 
 Cold Spring Harbor Laboratory Press on June 20, 2016 - Published by genome.cshlp.orgDownloaded from 
  
 
  
 
28
This work is funded by The Research Foundation - Flanders (FWO, www.fwo.be) (grants 
G.0640.13 and G.0791.14 to SA), Special Research Fund (BOF) KU Leuven 
(http://www.kuleuven.be/research/funding/bof/) (grant PF/10/016 and OT/13/103 to SA), 
Foundation Against Cancer (http://www.cancer.be) (grants 2010-154 and 2012-F2 to SA). 
AV is funded by a research grant from FWO and Kom op tegen kanker. ZKA is funded by a 
research grant from Kom of tegen kanker. KD and HI have PhD Fellowships from the agency 
for Innovation by Science and Technology (IWT, www.iwt.be). The funders had no role in 
study design, data collection and analysis, decision to publish, or preparation of the 
manuscript. 
 
Contributions  
SA obtained funding, conceived and supervised the study. AV developed the CHEQ-seq 
methodology and performed all experiments with the help of VC. AV processed the data with 
the help of KD, MF, HI, and ZKA. DS performed the analyses related to machine learning. 
MF performed the DNA shape analysis. SA and AV wrote the manuscript.  
 Cold Spring Harbor Laboratory Press on June 20, 2016 - Published by genome.cshlp.orgDownloaded from 
  
 
  
 
29
Figure legends 
Figure 1 – Overview of the CHEQ-seq reporter assay. (a) (I) Genomic DNA is sheared 
and custom baits are used to capture the regions of interest (ROI). (II) Captured ROIs are 
cloned into a reporter library consisting of a GFP-based reporter linked to a pool of 17 x109 
barcodes. (III) The reporter library is transfected under various conditions after which the 
RNA of transcribed barcodes is extracted. (IV) Randomly coupled ROI-barcode couples are 
identified using PacBio sequencing and barcode expression is measured using Illumina short-
read sequencing. (b-e) Four TP53 ChIP-seq peaks comparing the CHEQ-seq barcode level 
with luciferase activity of a manually cloned fragment. (f) CHEQ-seq and luciferase induction 
only agree when they both overlap with the ChIP-seq peak summit.  
 
Figure 2 – CHEQ-seq identifies TP53 responsive enhancers. (a) MAplot showing the 
distribution of CHEQ-seq barcode expression levels versus the fold induction, showing a 
large number of activation (green), and almost no repression (red). Negatives and greyzone 
are defined by thresholds on fold change and significance (see Methods). (b) CHEQ-seq 
positives are mostly positive or greyzone in STARR-seq (first bar), while down-regulated 
regions could not be confirmed by STARR-seq (second bar). * = p-value < 0.001 as 
determined by Chi-square.  (c) Positives from CHEQ-seq are also mostly (91%) positives in 
STARR-seq.  
 
Figure 3 – TP53 enhancer model (a) 10 motifs were selected from motif discovery tools i-
cisTarget, HOMER and RSAT peak motif. (b) Heatmap showing the best Cluster-Buster 
score for each peak of the non-responsive (negatives) and TP53-responsive (positives) subset. 
Discordance between PWM scores and CHEQ-seq are indicated with a yellow square. (c-e) 
Classification accuracy for each PWM shown as ROC curves. (f) Comparison between a 
single maximum score (red) versus a homotypic cluster of motifs (black dashed). (g) All 
positive regions with 1kb flanking sequence centered on the best scoring motif illustrating the 
absence of binding site clusters. (h-i) TP53 enhancers are binary on/off enhancers as shown 
 Cold Spring Harbor Laboratory Press on June 20, 2016 - Published by genome.cshlp.orgDownloaded from 
  
 
  
 
30
by the lack of correlation between the motif score and barcode expression (h), as well as the 
lack of correlation between the peak score and the barcode expression (i). 
 
Figure 4 – Only directly bound peaks behave as enhancers (a) The average basemean 
expression values indicate that the direct and indirect peaks show significantly different 
reporter activity levels (p-val = 3.28x10-51). (b) Comparison of TP53 ChIP-seq signal and 
H3K27ac ChIP-seq signal between positives and negatives. Peaks are extended to 2000bp 
each side. Heatmaps show the raw tag count coverage per peak. (c) The average differential 
expression of genes near (<20kb) peaks (asterisk indicates p-val of 4.73x10-8). (d) 
Comparison of the proportion of direct versus indirect ChIP-seq peaks across 15 publicly 
available TP53 ChIP-seq datasets. Experiments are ordered along the x-axis based on total 
number of peaks called. (e) Directly bound peaks agree, but indirectly bound do not, between 
in-house ChIP-seq peaks and other data sets. The percentage overlap is compared to the in-
house peaks. 
 
Figure 5 – TP53 binding is conserved across data sets. 15 public data sets containing ChIP-
seq against TP53 under various conditions were collected and remapped (also see 
Supplemental Table S7). 21649 predicted TP53 binding sites throughout the genome are 
clustered based on their coverage across all data sets and can be subdivided into shared strong 
(green), shared weak (yellow) and shared unbound (red) regions. On the bottom, individual 
aggregation plots show the coverage for each cluster per sample.  
 
Figure 6 –DNA features of TP53 responsive enhancers. (a) Sequence constraint 
(phastCons) of the DNA sequence around the predicted TP53 binding sites for the three 
classes (strongly bound, weakly bound, unbound). Inset: zoom in of the TP53 binding sites 
shows the highest conservation around the core C and G nucleotides. (b) Different features 
and different machine learning methods were tested individually and in combination for there 
ability to discriminate strongly bound from unbound binding sites. (c-d) Dinucleotide 
composition of the 800 bp sequence around the binding sites. Bound sequences (c) show 
 Cold Spring Harbor Laboratory Press on June 20, 2016 - Published by genome.cshlp.orgDownloaded from 
  
 
  
 
31
depletion of TT and AA (blue lines) and AT and TA (grey-black lines) at 100 bp flanking the 
binding site compared to unbound sequences (d). (e-g) DNA shape features within 700 bp 
sequences around the predicted binding sites. Grey region ~100 bp away from the binding site 
shows the strongest differences between bound and unbound sites.  
 
Figure 7 – Quantitative prediction of functional TP53 sites. (a) Heatmap showing the 
TP53 ChIP-seq coverage across all 16 datasets for the ~21000 predicted sites, after rank 
aggregation, alongside H3K27ac, DNase and GRO-seq status in untreated and TP53-
stabilizing conditions. The color gradient on the left indicates the original clusters from 
Figure 5. Smoothed scores on the right (DL = deep learning; RF = Random Forest; PWM 
score = position weight matrix score) show gradual decline with the meta-ranking. (b) For 
each binding site within the clusters the closest gene within 20kb was assigned and the 
average differential expression calculated using RNA-seq data. Only strongly bound sites 
associate with genes that are up-regulated upon TP53 stimulation compared to random control 
(p-val * = 2.45x10-10).  (c) CHEQ-seq barcode reporter increase is also correlated with the 
level of binding , as compared to random regions as control (p-val * = 9.83x10-49, ** =  
4.06x10-27, *** = 3.55x10-5).   
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